<DOC>
	<DOCNO>NCT01382147</DOCNO>
	<brief_summary>Evaluation weather early chemotherapy attempt remission induction improve result patient Acute Myeloid Leukemia ( AML ) , compare standard group .</brief_summary>
	<brief_title>Evaluation `` Dose-dense Therapy '' S-HAM Comparison Conventionally Timed Double Induction Patients With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Patients newly diagnose AML ( except acute promyelocytic leukemia ) accord WHO classification include patient secondary AML AML precede hematologic disorder Age 18 year old Informed consent . Before study specific procedure include randomisation do study medication administer , subject , legally acceptable representative , must give write informed consent participation study . Acute promyelocytic leukemia ( APL ) Previous concurrent malignancy AML Previous treatment colonystimulating factor , interleukin interferon Known hypersensitivity Escherichia coli derive product ( e.g . Filgrastim , HUMULIN® Insulin , LAsparaginase , HUMATROPE® Growth Hormone , INTRON A® ) Antibodybased cellbased immunotherapy Respiratory insufficiency pO2 &lt; 60 mmHg Heart failure NYHA III° IV° Elevated creatinine &gt; 2.0 mg/dl Elevated bilirubin &gt; 2.0 mg/dl Pregnancy lactation Females without adequate contraception Known HIV and/or hepatitis C infection Severe neurologic psychiatric disease Psychiatric , addictive , disorder , compromise ability give truly informed consent participation study Concerns subject 's compliance protocol procedure Lack willingness record circulate personal diseaserelated information define study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>